medigraphic.com
Colegio de Medicina Interna de México.

2006, Number 3

<< Back Next >>

Med Int Mex 2006; 22 (3)

Prevalence of hypertension and metabolic syndrome in a sample of Mexican population

Suárez OR, Gutiérrez BJ

Language: Spanish
References: 21
Page: 183-188
PDF size: 250.42 Kb.


ABSTRACT

Background: Cardiovascular mortality is increasing in developing countries; hypertension and metabolic syndrome are major risk factors.
Objective: To determine the hypertension and metabolic syndrome prevalence according to the new definition.
Participants and methods: A cross-sectional survey in patient's relatives was done. We took clinical history, measured blood pressure, weight, height and waist circumference on first visit and scheduled a next day visit where we measured blood pressure, glucose, cholesterol, triglycerides, HDL and LDL cholesterol. A person was considered hypertensive when systolic and diastolic pressure was ≥140 mmHg or ≥90 mmHg in both visits or a previous diagnosis. For diagnosis of metabolic syndrome, IFD classification was used.
Results: 247 individuals were studied, 3 were eliminated from analysis, 144 (59%) were female, 49 (20.1%) were known hypertensive, and 36(14.7%) showed high blood pressure on first visit but in only 22 (9%) it was confirmed on second. Prevalence in our sample was 29.5% (95% IC 26.6 a 35.4). 31.3% (95%CI 23.3 a 39.2) in women and 27% (95%CI 18.6 a 36.8) in men. The metabolic syndrome prevalence was 46.7% (95%CI 40 a 53), higher in women 56% (95%CI 47.8 a 64.7) than men 33% (95%CI 24 a 34.3). The cardiovascular risk factors were more prevalent among hypertensive individuals.
Discussion: Hypertension and metabolic syndrome are highly prevalent in our population, its prevalence is affected by characteristics of studied sample and diagnostic criteria used, the prevalence of metabolic syndrome is higher than in previous reports in Mexico.


REFERENCES

  1. Chobanian AV, Bakris GL, Blanck HR, et al. Seventh report of the Joint National Committee on Prevention, Detection Evaluation and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.

  2. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension analysis of world wide data. Lancet 2005;365:217-23.

  3. Velásquez O, Rosas M, Lara A, et al. Hipertensión arterial en México: Resultados de la Encuesta Nacional de Salud 2000. Arch Cardiol Mex 2002;72:71-84.

  4. Lara A, Rosas M, Pastelín G, et al. Hipercolesterolemia e hipertensión arterial en México. Consolidación urbana actual con obesidad, diabetes y tabaquismo. Arch Cardiol Mex 2004;74:231-45.

  5. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organization; 1999. Disponible en: http://whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf Acceso junio 21, 2005.

  6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.

  7. International Diabetes Federation. The IDF Consensus worldwide definition of the metabolic syndrome. Brussels: International Diabetes Federation, 2004. http://www.idf.org/webdata/docs/IDF_Metasyndrome_definition.pdf Acceso mayo 2, 2005.

  8. Guidelines Committee 2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Hypertension. J Hypertens 2003;21:1011-53.

  9. Rosas M, Pastelín G, Martínez J, Herrera-Acosta J, Attie F. Hipertensión Arterial en México: guías y recomendaciones para su detección, control y tratamiento. Arch Cardiol Mex 2004;74:134-57.

  10. Cutler JA, MacMahon SW, Furberg CD. Controlled clinical trials of drug treatment for hypertension. Hypertension 1989;13:136-44.

  11. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.

  12. Dahlöf B, Deveroux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE). Lancet 2002;359:995-1003.

  13. Hankey GJ. Angiotensin-converting enzyme inhibitors for stroke prevention. Stroke 2003;34:354-6.

  14. Pierdomenico SD, Mezzetti A, Lapenna D, et al. ‘White-coat’ hypertension in patients with newly diagnosed hypertension: evaluation of prevalence by ambulatory monitoring and impact on cost of health care. Eur Heart J 1995;16:692-7.

  15. Giles TD. The new definition of hypertension. Program and abstracts from the 20th Annual Scientific Meeting of the American Society of Hypertension; May 14-18, 2005; San Francisco, California.

  16. Aguilar-Salinas CA, Rojas R, Gómez Pérez FJ, et al. High prevalence of metabolic syndrome in Mexico. Arch Med Res 2004;35:76-81.

  17. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. JAMA 2002;287:356-9.

  18. Ninomiya JK, L’Italien G, Criqui MH, et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2005;109:42-46.

  19. Koren-Morag N, Goldbourt U, Tanne D. Relation between the metabolic syndrome and ischemic stroke and transient ischemic attack. Stroke 2005;36:1366-71.

  20. Carroll S, Dudfield M. What is the relationship between exercise and metabolic abnormalities? Sports Med 2004;34:371-418.

  21. Grupo de Estudio del Síndrome Metabólico. Consenso Mexicano sobre el Tratamiento Integral del Síndrome Metabólico. Rev Mex Cardiol 2002;13:4-30.




2020     |     www.medigraphic.com